Biohaven Ltd.: Business Overview, Financials & Competitive Analysis
Biohaven Ltd. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage biotech with multiple pivotal readouts in 2H 2026, strong cash position, and proprietary degrader platforms offers compelling milestone risk-reward despite current trading discount. Biohaven maintains strong liquidity with $351.8M in cash as of March 31, 2026, while Q1 2026 R&D expenses were $103.8M. Multiple pivotal trial initiations and topline.
What is Biohaven Ltd.'s industry? Biohaven Ltd. (biohavenpharma.com) operates in Pharmaceuticals. AskCyborg classifies Biohaven Ltd. under Pharmaceuticals in its company registry.
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. The company is a...
Cyborg Score thesis
Clinical-stage biotech with multiple pivotal readouts in 2H 2026, strong cash position, and proprietary degrader platforms offers...
Read the full analyst-debate transcript →Get the Latest Biohaven Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBiohaven Ltd. Overview
Pro stress-test →Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. The company is advancing a diverse pipeline across immunology, neuroscience, and oncology therapeutic areas with multiple pivotal trials and clinical readouts expected in the second half of 2026.
Strategic Profile
Pro stress-test →Biohaven is advancing its novel MoDE and TRAP extracellular protein degradation platforms into two pivotal studies—BHV-1300 for Graves' disease and BHV-1400 for IgA nephropathy. Late-stage programs include a pivotal epilepsy program with opakalim, with expected topline results in H2 2026, and a Phase 2 obesity study with taldefgrobep alfa, with topline data expected in H2 2026.
Competitive Landscape
Pro stress-test →Biohaven competes with biotech firms including Neurogene, Quince Therapeutics, Alector, Design Therapeutics, and CuraSen. As a clinical-stage player, the company faces competition from both larger pharma (in rare disease immunology and neurology) and emerging biotech focused on protein degradation platforms and metabolic disorders. Biohaven's differentiation rests on proprietary MoDE and TRAP degrader technologies and its multi-indication pipeline.
Industry Context
Biohaven Ltd. operates in Pharmaceuticals.
Key facts
Headquarters: New Haven, Connecticut · Market cap: $1.42B